Perjeta

Roche's newer breast cancer drugs gain traction

Perjeta and Kadcyla boost 2014 revenues. Solid growth for Roche's breast cancer blockbuster Herceptin was backed up by big gains for two follow-up products in the last quarter for ... Roche's breast cancer franchise was particularly boosted by the

Pharma condemns Cancer Drugs Fund cuts

Among the more contemplative companies was Roche, which escaped having newer cancer drugs such as Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) removed from the list, although the CDF will no longer

Double trial disappointment for Roche

The regimens were Kadcyla plus Roche's Perjeta (pertuzumab), Kadcyla alone and Herceptin plus taxane chemotherapy.

Novartis' Afinitor fails frontline breast cancer trial

Afinitor conferred a seven-month improvement in PFS, and while this may warrant further study emerging data for other treatment regimens - such as the combination of Herceptin with Roche's Perjeta

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Kadcyla (trastuzumab emtansine). Breast cancer. Perjeta (pertuzumab). Breast cancer. Sanofi. Jevtana (cabazitaxel).

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]